McKesson Corporation — 7.4/10
McKesson Corporation is the North American pharmaceutical-distribution leader (fiscal year ends March 31). It is one of three wholesalers — with Cencora and Cardinal Health — that control more than 90% of US pharmaceutical distribution, holding roughly 33% individual share. North American Pharmaceutical is ~83% of revenue and grows at/above GDP with structurally expanding adjusted operating profit; the fastest-growing exposure, Oncology & Multispecialty (+31% in FY2026), rides a double-digit specialty/oncology theme where MCK is a co-leader.
The core tension: MCK is a genuinely high-quality oligopoly compounder that clears all three quality-gate criteria — but the quality is already broadly recognized. Revenue growth decelerated through FY2026 (from a +23% easy-comp opening quarter to +6% in the latest), the sell side is a Strong Buy with zero Sell ratings, insiders are net sellers, and a persistent regulatory overhang (a reopened $2.5B West Virginia opioid suit plus 340B/IRA/tariff noise) caps the multiple. The offset: MCK trades ~2 turns below its slower-growing peers on forward P/E with ~31% ROIC and a clean balance sheet.
| CEO / CFO | Brian Tyler / Britt Vitalone (both since 2019) | Revenue Growth | Decelerating (+6.0% FQ4'26 YoY) |
| Market Position | 1 of Big 3 (~33% share, > 90% combined) | FCF Trajectory | Positive and growing; shares −5%/yr |
| ROIC / Net Debt-EBITDA | ~31% / 0.66x | FYE | March 31 |
| Quality Gate | PASS (0 NOs) | Margin Trend | Expanding |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 7 | 25% | 1.75 |
| Thematic Exposure | 8 | 35% | 2.80 |
| Management Quality | 8 | 20% | 1.60 |
| Investor Sentiment (Inverted) | 4 | 5% | 0.20 |
| Concerns / Risks | 7 | 15% | 1.05 |
| Composite | 100% | 7.4 |
A high-quality oligopoly compounder that clears all three quality-gate criteria and lands at 7.4/10. MCK is the scaled #1 in the > 90%-controlled US pharmaceutical-distribution oligopoly (~33% share), with adjusted operating margin expanding (operating profit +15% outgrowing revenue +12%), a durable ~5%/yr share-count decline, positive-and-growing FCF, and a beat-and-raise management team (raised FY2026 EPS all four quarters then beat it; ROIC ~31%). Layered on top is a +31% community-oncology grower where MCK is a co-leader vertically integrating into the provider demand side. Valuation is supportive: ~17.3x FY2027 P/E, roughly 2 turns below the Cencora/Cardinal Health peer average.
Quality gate: PASS (0 NOs). Oligopoly YES. Positive & growing FCF YES. Management track record YES. All three clear, so the composite scores normally with no cap.
MCK is the rare name where the highest-weight dimensions — thematic (8) and management (8) — are the strongest, and the drags sit in the lower-weight ones. Thematic exposure earns an 8 on a textbook entrenched oligopoly plus a genuine high-growth oncology theme; it falls short of a perfect 10 only because the dominant book is a razor-thin-margin, price-taking distribution franchise rather than a dominant-share pricing-power monopoly, and the fragmented Med-Surg tail is being spun off.
Financial trends land at 7: the profile is margin-led and genuinely levered (operating profit outgrowing revenue), but the "accelerating revenue" leg of a 10 is missing — YoY growth decelerated from +23% to +6% through FY2026 and the FY2027 guide resets to +5–9%.
The two lower-weight dimensions are what keep the composite at 7.4 rather than higher. Investor sentiment (inverted) is a 4: a crowded, well-understood long where management and the street agree, with insiders net sellers — no contrarian edge to exploit. Concerns/risks earn a 7 on a below-peer valuation and effectively zero China exposure, capped by a persistent regulatory overhang (reopened $2.5B WV opioid suit, 340B/IRA/tariff noise) and an FY2027 FCF guide that dips below FY2026 actual.